CytoDyn (OTCQB:CYDY) said on Tuesday that data supports a new way its drug leronlimab, a CCR5 antagonist, may help treat ...

CytoDyn (CYDN) stock rises as lead asset leronlimab shows promise in boosting PD-L1 levels in solid tumors. Read more here.

Researchers at Baylor College of Medicine and collaborating institutions have uncovered a key molecular player that is involved in lung repair and in ...

Cancer treatment with a cell-based immunotherapy causes mild cognitive impairment, a Stanford Medicine team found. They also identified compounds that could treat it.

Swedish cancer patients treated with CAR T-cell therapy show better survival rates and fewer side effects than seen in ...

In recent years, cell therapies have developed alongside chemotherapy and immunotherapy to become a new pillar in the treatment of patients with blood and lymph gland cancer. In solid tumors ...

The new CAR-T approach targets tumors directly, bypassing the blood-brain barrier, potentially offering more durable and sustained efficacy. The FDA granted breakthrough therapy designation to an ...

EchoBack CAR T-cells are smart immune warriors that respond to ultrasound to fight cancer longer and more safely than ever before. They promise a big leap in treating solid tumors. Credit: ...

Here we demonstrate that DuoHexaBody-CD37 induces direct cytotoxicity in DLBCL-derived tumor cell lines independent of the subtype. DuoHexaBody-CD37 induced significant CD37 clustering and was ...

The tumor microenvironment—the complex environment that surrounds cancer cells—is often deprived of nutrients and oxygen, particularly in hard-to-treat cancers like pancreatic cancer.